Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > New drug target identified for inflammatory lung disease

New drug target identified for inflammatory lung disease

Date time 4 July, 2022
News Type News type Media release
Dr Gang Liu
Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.

Secreted by mast cells, a part of the immune system, the drug target is an enzyme known as mast cell chymase-1 (CMA1).

CMA1 was found by the researchers to actively promote and progress the development of COPD. Inhibiting the equivalent enzyme in mice was shown to provide protection in experimental models of COPD. New drugs targeting CMA1, said the researchers, could offer up a new therapeutic approach to tackling COPD which affects more than 300 million people globally.

Dr Gang Liu, the study’s lead author and researcher at the Centenary UTS Centre for Inflammation said that COPD was caused by cigarette smoke, air pollution, as well as bushfire smoke and other particulate matter.

“Over time the lungs breathe in toxic material and become inflamed. Lung function is subsequently impaired leading to breathing difficulties which can then turn fatal,” said Dr Liu.

In their new study, the researchers discovered elevated CMA1 levels in the lung tissues of patients with severe COPD – the CMA1 levels were approximately double that found in the lung tissue of mild-COPD patients and healthy individuals.

“CMA1 induces macrophages (a type of white blood cell) to release pro-inflammatory cytokines in the lung. It’s this increased inflammation that can drive the development of COPD and poor outcomes for patients,” said Dr Liu.

Subsequent investigation of the equivalent CMA1 enzyme found in mice – an enzyme known as mMCP5 – confirmed the enzyme’s pivotal role in COPD.

“We were able to show in experimental COPD, that inhibiting mMCP5 provided protection against inflammation and macrophage accumulation, harmful structural changes of the lung, emphysema and impaired lung function,” Dr Liu said.

Professor Phil Hansbro, the study’s senior author and Director of the Centenary UTS Centre for Inflammation said the team’s research offered up a new therapeutic target to help combat COPD.

“There is currently no cure for COPD and effective therapies to treat and manage the disease are urgently needed. Our study suggests that developing new drugs to inhibit CMA1 and reduce cytokine inflammation may be a novel treatment for this devastating disease that affects so many lives,” Professor Hansbro said.

The study was published in the European Respiratory Journal.

Themes

  • Inflammation

    Inflammation

Programs

  • Centenary UTS Centre for Inflammation

Research Fields

  • COPD – Chronic obstructive pulmonary disease

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

New drug target identified for inflammatory lung disease

Download

Recent Stories

  • Metastatic cancer research boosted

    Dr Dannel Yeo from the Centenary Institute and Clinical Associate Professor Kate Mahon from Chris O’Brien Lifehouse, have been awarded an inaugural Sydney Cancer Partners Translational Fellowship.
    News Type: Research News
    Date 03 Mar 2023
  • The Year That Made Me: Professor John Rasko

    Professor John Rasko AO, Head of the Gene and Stem Cell Therapy Program at the Centenary Institute has featured on the popular Radio National show Sunday Extra in the segment called ‘The Year That Made Me’.
    News Type: Media coverage
    Date 21 Feb 2023
  • Top abstract prize for gene therapy research

    Professor John Rasko AO and team have received the top scoring abstract award at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders in Manchester.
    News Type: Research News
    Date 15 Feb 2023
  • Event celebrates ‘The Good Gut Anti-Inflammatory Diet’

    The Centenary Institute has celebrated the publication of a new book, 'The Good Gut Anti-Inflammatory Diet’ at a special event, held at the Dymocks Bookstore, Sydney.
    News Type: Community
    Date 13 Feb 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram